bucindolol has been researched along with arginine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Clark, AL; Cleland, JG; Coletta, AP; Ingle, L; Lalukota, K | 1 |
| Couzin, J | 1 |
1 review(s) available for bucindolol and arginine
| Article | Year |
|---|---|
Clinical trials update from the Heart Failure Society of America: EMOTE, HERB-CHF, BEST genetic sub-study and RHYTHM-ICD.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Arginine; Cardiotonic Agents; Cardiovascular Agents; Crataegus; Cyclic Nucleotide Phosphodiesterases, Type 3; Enoximone; Enzyme Inhibitors; Exercise Tolerance; Heart Failure; Homozygote; Humans; Oxygen Consumption; Plant Extracts; Propanolamines; Randomized Controlled Trials as Topic; Receptors, Adrenergic, beta-1; Societies, Medical; Stroke Volume; Survival Analysis; Treatment Failure; Treatment Outcome; United States | 2004 |
1 other study(ies) available for bucindolol and arginine
| Article | Year |
|---|---|
American Association for the Advancement of Science meeting. DNA tells story of heart drug failure.
Topics: Adrenergic beta-Antagonists; Arginine; Cardiac Output, Low; Glycine; Humans; Pharmacogenetics; Polymorphism, Genetic; Propanolamines; Randomized Controlled Trials as Topic; Receptors, Adrenergic, beta-1 | 2005 |